natszdravНациональное здравоохранениеNational Health Care (Russia)2713-069X2713-0703Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)10.47093/2713-069X.2021.2.1.5-11natszdrav-104Research ArticleПЕРЕДОВАЯ СТАТЬЯEDITORIALОрганизационные аспекты вакцинации против новой коронавирусной инфекцииOrganizational aspects of vaccination against a new coronavirus infectionhttps://orcid.org/0000-0002-4426-0088МурашкоМ. А.MurashkoM. A.

Мурашко Михаил Альбертович – доктор медицинских наук, профессор, министр здравоохранения РФ

пер. Рахмановский, д. 3, ГСП-4, г. Москва, 127994

Mikhail A. Murashko – Dr. of Sci. (Medicine), Professor, Minister of Health of the Russian Federation.

Rakhmanovsky lane, 3, GSP-4, Moscow, 127994

https://orcid.org/0000-0001-6581-4521ДрапкинаО. М.DrapkinaO. M.

Драпкина Оксана Михайловна –доктор медицинских наук, профессор, член-корреспондент РАН, директор 

Петроверигский пер., д. 10, г. Москва, 101990

Oksana M. Drapkina – Dr. of Sci. (Medicine), Professor, Corresponding Member of the Russian Academy of Science, Director

Petroverigsky lane, 10, Moscow, 101990

ODrapkina@gnicpm.ruМинистерство здравоохранения Российской ФедерацииРоссияMinistry of Health of the Russian FederationRussian FederationФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава РоссииРоссияNational Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian FederationRussian Federation20211409202121511Copyright © Мурашко М.А., Драпкина О.М., 20212021Мурашко М.А., Драпкина О.М.Murashko M.A., Drapkina O.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.natszdrav.ru/jour/article/view/104

.

.

ReferencesPlotkin S. History of vaccination. Proc Natl Acad Sci USA. 2014; 111(34): 12283–12287. https://doi.org/10.1073/pnas.1400472111 PMID: 25136134Plotkin S. History of vaccination. Proc Natl Acad Sci USA. 2014; 111(34): 12283–12287. https://doi.org/10.1073/pnas.1400472111 PMID: 25136134WHO. https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1 (accessed 04.07.2021).WHO. https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1 (accessed 04.07.2021).Thanh Le T., Andreadakis Z., Kumar A., et al. The COVID-19 vaccine development land- scape. Nat Rev Drug Discov. 2020; 19(5): 305–306. https://doi.org/10.1038/d41573-020-00073-5 PMID: 32273591Thanh Le T., Andreadakis Z., Kumar A., et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020; 19(5): 305–306. https://doi.org/10.1038/d41573-020-00073-5 PMID: 32273591WHO. Draft landscape of COVID-19 candidate vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (accessed 30.03.2020).WHO. Draft landscape of COVID-19 candidate vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (accessed 30.03.2020).Zhao J., Zhao S., Ou J., et al. COVID-19: Coronavirus Vaccine Development Updates. Front Immunol. 2020; 11: 602256. https://doi.org/10.3389/fimmu.2020.602256 PMID: 33424848Zhao J., Zhao S., Ou J., et al. COVID-19: Coronavirus Vaccine Development Updates. Front Immunol. 2020; 11: 602256. https://doi.org/10.3389/fimmu.2020.602256 PMID: 33424848Iversen P.L., Bavari S. Inactivated COVID-19 vaccines to make a global impact. Lancet Infect Dis. 2021; 21(6): 746–748. https://doi.org/10.1016/S1473-3099(21)00020-7 PMID: 33548196Iversen P.L., Bavari S. Inactivated COVID-19 vaccines to make a global impact. Lancet Infect Dis. 2021; 21(6): 746–748. https://doi.org/10.1016/S1473-3099(21)00020-7 PMID: 33548196Lundstrom K. Viral Vectors in Gene Therapy. Diseases. 2018; 6(2): 42. https://doi.org/10.3390/diseases6020042Lundstrom K. Viral Vectors in Gene Therapy. Diseases. 2018; 6(2): 42. https://doi. org/10.3390/diseases6020042Schiedner G., Morral N., Parks R.S., et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat. Genet. 1998; 18: 180–183. https://doi.org/10.1038/ng0298-180Schiedner G., Morral N., Parks R.S., et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat. Genet. 1998; 18: 180–183. https://doi.org/10.1038/ng0298-180Wise J. Covid-19: New data on Oxford AstraZeneca vaccine backs 12 week dosing interval BMJ 2021; 372: n326. https://doi.org/10.1136/bmj.n326Wise J. Covid-19: New data on Oxford AstraZeneca vaccine backs 12 week dosing interval BMJ 2021; 372: n326. https://doi.org/10.1136/bmj.n326He Q., Mao Q., An Ch., et al. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates, Emerging Microbes & Infections. 2021; 10(1): 629–637. https://doi.org/10.1080/22221751.2021.1902245He Q., Mao Q., An Ch., et al. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates, Emerging Microbes & Infections. 2021; 10(1): 629–637. https://doi.org/10.1080/22221751.2021.1902245Logunov D.Y., Dolzhikova I.V., Zubkova O.V., et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous primeboost COVID-19 vaccine in two for- mulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020; 396(10255): 887–897. https://doi.org/10.1016/S0140-6736(20)31866-3Logunov D.Y., Dolzhikova I.V., Zubkova O.V., et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous primeboost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020; 396(10255): 887–897. https://doi.org/10.1016/S0140-6736(20)31866-3Kwak H., Honig H., Kaufmann H.L. Poxviruses as vectors for cancer immunotherapy. Curr. Opin. Drug Discov. Devel. 2003; 6(2): 161–168. PMID: 12669450Kwak H., Honig H., Kaufmann H.L. Poxviruses as vectors for cancer immunotherapy. Curr. Opin. Drug Discov. Devel. 2003; 6(2): 161–168. PMID: 12669450Hussein Y. Naim. Measles virus. A pathogen, vaccine, and a vector. Human Vaccines & Immunotherapeutics, 2015; 11(1): 21–26. https://doi.org/10.4161/hv.34298Hussein Y. Naim. Measles virus. A pathogen, vaccine, and a vector. Human Vaccines & Immunotherapeutics, 2015; 11(1): 21–26. https://doi.org/10.4161/hv.34298WHO recommendation Moderna COVID-19 mRNA Vaccine (nucleoside modified). https://extranet.who.int/pqweb/vaccines/covid-19-mrna-vaccine-nucleoside-modified (accessed 04.07.2021).WHO recommendation Moderna COVID-19 mRNA Vaccine (nucleoside modified). https://extranet.who.int/pqweb/vaccines/covid-19-mrna-vaccine-nucleoside-modified (accessed 04.07.2021).Tang D.C., DeVit M., Johnston S.A. Genetic immunization is a simple method for eliciting an immune response. Nature. 1992; 356: 152–154. https://doi.org/10.1038/356152a0Tang D.C., DeVit M., Johnston S.A. Genetic immunization is a simple method for eliciting an immune response. Nature. 1992; 356: 152–154. https://doi.org/10.1038/356152a0Ulmer J.B., Donnelly J.J., Parker S.E., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993; 259: 1745–1749. https://doi.org/10.1126/science.8456302Ulmer J.B., Donnelly J.J., Parker S.E., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993; 259: 1745–1749. https://doi.org/10.1126/science.8456302Wang B., Agadjanyan M.G., Srikantan V., et al. Molecular cloning, expression, and biological characterization of an HTLV-II envelope glycoprotein: HIV-1 expression is permissive for HTLV-II-induced cell fusion. AIDS Res Hum Retroviruses. 1993; 9: 849–860. https://doi.org/10.1089/aid.1993.9.849Wang B., Agadjanyan M.G., Srikantan V., et al. Molecular cloning, expression, and biological characterization of an HTLV-II envelope glycoprotein: HIV-1 expression is permissive for HTLV-II-induced cell fusion. AIDS Res Hum Retroviruses. 1993; 9: 849–860. https://doi.org/10.1089/aid.1993.9.84918Fynan E.F., Webster R.G., Fuller D.H., et al. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA. 1993; 90: 11478–11482. https://doi.org/10.1073/pnas.90.24.11478Fynan E.F., Webster R.G., Fuller D.H., et al. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA. 1993; 90: 11478–11482. https://doi.org/10.1073/pnas.90.24.11478Ferraro B., Morrow M.P., Hutnick N.A., et al. Clinical applications of DNA vaccines: current progress. Clin Infect Dis. 2011; 53(3): 296–302. https://doi.org/10.1093/cid/cir334Ferraro B., Morrow M.P., Hutnick N.A., et al. Clinical applications of DNA vaccines: current progress. Clin Infect Dis. 2011; 53(3): 296–302. https://doi.org/10.1093/cid/cir334Clinical trials arena. https://www.clinicaltrialsarena.com/analysis/coronavirus-merscov-drugs/ (accessed 04.07.2021).Clinical trials arena. https://www.clinicaltrialsarena.com/analysis/coronavirus-merscov-drugs/(accessed 04.07.2021).Okino M., Mohri H. Effects of a high-voltage electrical impulse and an anticancer drug on in vivo growing tumors. Jpn J Cancer Res. 1987; 78: 1319–1321. PMID: 2448275Okino M., Mohri H. Effects of a high-voltage electrical impulse and an anticancer drug on in vivo growing tumors. Jpn J Cancer Res. 1987; 78: 1319–1321. PMID: 2448275Titomirov A.V., Sukharev S., Kistanova E. In vivo electroporation and stable transformation of skin cells of newborn mice by plasmid DNA. Biochim Biophys Acta. 1991; 1088: 131–134. https://doi.org/10.1016/0167-4781(91)90162-FTitomirov A.V., Sukharev S., Kistanova E. In vivo electroporation and stable transformation of skin cells of newborn mice by plasmid DNA. Biochim Biophys Acta. 1991; 1088: 131–134. https://doi.org/10.1016/0167-4781(91)90162-FHirao L.A., Wu L., Khan A.S., et al. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine. 2008; 26(25): 3112–3120. https://doi.org/10.1016/j.vaccine.2008.02.036Hirao L.A., Wu L., Khan A.S., et al. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine. 2008; 26(25): 3112–3120. https://doi.org/10.1016/j.vaccine.2008.02.036Top D., Barry C., Racine T., et al. Enhanced fusion pore expansion mediated by the transacting Endodomain of the reovirus FAST proteins. PLoS Pathog. 2009; 5(3): e1000331. https://doi.org/10.1371/journal.ppat.1000331Top D., Barry C., Racine T., et al. Enhanced fusion pore expansion mediated by the transacting Endodomain of the reovirus FAST proteins. PLoS Pathog. 2009; 5(3): e1000331. https://doi.org/10.1371/journal.ppat.1000331Hulswit R. J. G., de Haan C. A. M., Bosch B.-J. Coronavirus Spike Protein and Tropism Changes. Advances in Virus Research. 2016; 29–57. https://doi.org/10.1016/bs.aivir.2016.08.004Hulswit R. J. G., de Haan C. A. M., Bosch B.-J. Coronavirus Spike Protein and Tropism Changes. Advances in Virus Research. 2016; 29–57. https://doi.org/10.1016/bs.aivir.2016.08.004Zhao J., Zhao S., Ou J., et al. COVID-19: Coronavirus Vaccine Development Updates. Front Immunol. 2020; 11: 602256. https://doi.org/10.3389/fimmu.2020.602256 PMID: 33424848Zhao J., Zhao S., Ou J., et al. COVID-19: Coronavirus Vaccine Development Updates. Front Immunol. 2020; 11: 602256. https://doi.org/10.3389/fimmu.2020.602256 PMID: 33424848Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., et al. Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021; 397(10275): 671–681. https://doi.org/10.1016/S0140-6736(21)00234-8 PMID: 33545094Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., et al. Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021; 397(10275): 671–681. https://doi.org/10.1016/S0140-6736(21)00234-8 PMID: 33545094Рыжиков А.Б., Рыжиков Е.А., Богрянцева М.П. и др. Простое слепое плацебо-контролируемое рандомизированное исследование безопасности, реактогенности и иммуногенности вакцины «ЭпиВакКорона» для профилактики COVID-19 на добровольцах в возрасте 18–60 лет (фаза I–II). Инфекция и иммунитет. 2021; 11(2): 283– 296. https://doi.org/10.15789/2220-7619-ASB-1699Ryzhikov A. B., Ryzhikov E. A., Bogryantseva M. P., et al. A simple blind placebocontrolled randomized trial of the safety, reactogenicity and immunogenicity of the EpiVacCorona vaccine for the prevention of COVID-19 on volunteers aged 18–60 years (phase I and II). Infection and immunity. 2021; 11(2): 283–296 (in Russian). https://doi.org/10.15789/2220-7619-ASB-1699Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19. https://www.clinicaltrials.gov/ct2/show/NCT04780035?term=vaccine&cond=Covid19&draw=2 (accessed 04.07.2021).Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19. https://www.clinicaltrials.gov/ct2/show/NCT04780035?term=vaccine&cond=Covid19&draw=2 (accessed 04.07.2021).Государственный реестр лекарственных средств. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=71035dbe-6178-42c0-8d36-aa54e546a65b&t= (дата обращения: 04.07.2021).The State Register of Medicines (in Russian). https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=71035dbe-6178-42c0-8d36-aa54e546a65b&t= (accessed 04.07.2021)

The authors declare that there are no conflicts of interest present.